Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Riester

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
Journal of Experimental & Clinical Cancer Research : CR|June 2, 2022
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumorsStephen L Chan, Martin Schuler, Yoon-Koo Kang, et al.
Nature Communications|January 16, 2019
Author Correction: Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular featuresJason J Pitt, Markus Riester, Yonglan Zheng, et al.
Nature Communications|October 18, 2018
Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular featuresJason J Pitt, Markus Riester, Yonglan Zheng, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
Journal of Experimental & Clinical Cancer Research : CR|June 2, 2022
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumorsStephen L Chan, Martin Schuler, Yoon-Koo Kang, et al.
Nature Communications|January 16, 2019
Author Correction: Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular featuresJason J Pitt, Markus Riester, Yonglan Zheng, et al.
Nature Communications|October 18, 2018
Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular featuresJason J Pitt, Markus Riester, Yonglan Zheng, et al.
Pageof 5